Join to view full profile
C4 Therapeutics, Inc490 Arsenal Way, Suite 100Watertown, MA 02472
Dr. Crystal is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Medical oncologist (MD-PhD), board certified; Industry experience in early phase oncology drug development including small molecules, IO and CAR-T; Translational research: acquired resistance to targeted therapy in lung cancer.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2013
Mass General Brigham/Massachusetts General HospitalInternship, Internal Medicine, 2006 - 2007
Perelman School of Medicine at the University of PennsylvaniaClass of 2006
Certifications & Licensure
MA State Medical License 2008 - 2027
Publications & Presentations
PubMed
- 14 citationsDiscovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9.Katrina L Jackson, Ning Yin, Roman V Agafonov, Prasoon Chaturvedi, Kyle Cole
Journal of Medicinal Chemistry. 2025-12-11 - 27 citationsA Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Ca...Komal Jhaveri, Dejan Juric, Yoon Sim Yap, Sara Cresta, Rachel M. Layman
Clinical Cancer Research. 2021-11-01 - 729 citationsProspects for combining targeted and conventional cancer therapy with immunotherapyPhilip Gotwals, Scott Cameron, Daniela Cipolletta, Viviana Cremasco, Adam S. Crystal
Nature Reviews. Cancer. 2017-05-01
Press Mentions
Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingApril 18th, 2023
Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business HighlightsMarch 27th, 2023
AACR: C4's Multiple Myeloma Data Prompts Dosing Switch, Giving Patients a Longer Treatment ReprieveApril 8th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
